Orthobiologics Market Size Worth $11.77 Billion By 2030 | CAGR: 5.2%

The global orthobiologics market size is expected to reach USD 11.77 billion by 2030, according to a new study by Polaris Market Research. The report “Orthobiologics Market Share, Size, Trends, Industry Analysis Report, By Product (Demineralized Bone Matrix(DBM), Allograft, Bone Morphogenetic Protein (BMP), Viscosupplementation, Synthetic Bone Substitutes, Stem Cell Therapy, and Others); By Application; By End-Use; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increased use of platelet-rich plasma, homologous conditioned plasma, and adipose-generated stromal cell treatment is also predicted to contribute to market expansion. Orthobiologics, which are most usually connected with sports injuries, are organic substances, including platelet-rich plasma (PRP) or stem cells, that are used to accelerate the recovery process for musculoskeletal problems.

They can be used alone as well as in conjunction with traditional pharmacological and non-pharmaceutical therapy options. Orthobiologic therapies, in particular, consider introducing large concentrations of natural sources of cellular ingredients to an injury site to accelerate the recovery process of muscles, ligaments, soft tissue, joints, and other organs, thereby reducing recovery time and due to injuries pain, and swelling.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/orthobiologics-market/request-for-sample

Further, the development in the occurrence of sports injuries and road accidents is likely to drive the growth of the market during the forecast period. As per the John Hopkins Medicines, in the United States, about 30 million children and teenagers participate in some type of sports, and every year, around 3.5 million injuries occur, which results in some loss of engagement time.

Thus, orthobiologic therapies are utilized in sports medicine to treat either acute or chronic disorders, including typical overuse injuries. Athletes and orthopedists frequently turn to orthobiologic therapy to quickly recover an athlete to the pre-injury physical state. Most orthopedists will try to employ biologics instead of medications and/or intrusive surgery.

Furthermore, the rise in the prevalence of spinal illnesses and disorders is expected to fuel the expansion of the market. For instance, as per the National Spinal Cord Injury Statistical Center, the average annual incidence of SCI is around 54 instances per one million individuals, or approximately 17,810 additional SCI cases each year.

As per the WHO, every year, approximately 250 000 and 500 000 people worldwide develop a spinal cord injury (SCI). Most spinal cord accidents are caused by avoidable causes such as car accidents and falls. Therefore, the rising prevalence of sports injuries along with spinal disorders are the factors that are boosting the demand for orthobiologics therapy or treatment and are driving the market growth.

Orthobiologics Market Report Highlights

• The soft tissue injuries segment is anticipated to grow at the fastest CAGR over the forecast period owing to a rise in sports-related injuries and the desire for orthobiologics for cartilage regeneration.
• Spinal fusion segment accounted for a significant share of the global revenue due to the rising use of artificial matrices and allografts in spine fusion surgeries.
• Asia Pacific is expected to witness substantial growth over the projected period. This is growing owing to increased healthcare spending, rising disposable personal wealth, and an increase in road traffic accidents in various nations. The public funding for health education and services is also rising.
• The global players include Alphatec Spine Incorporation, DePuy Synthes, Incorporation, Exactech, Inc., Globus Medical, Inc., Globus Medical, Inc., Harvest Technologies Corporation, Orthofix Holdings, Inc., Stryker Corporation, SeaSpine Holdings Corporation, Wright Medical Group N.V., and Zimmer Biomet, Inc.

Polaris Market Research has segmented the Orthobiologics market report based on product, application, end-use, and region:

Orthobiologics, Product Outlook (Revenue - USD Billion, 2018 - 2030)

• Demineralized Bone Matrix(DBM)
• Allograft
• Bone Morphogenetic Protein (BMP)
• Viscosupplementation
• Synthetic Bone Substitutes
• Stem Cell Therapy
• Others

Orthobiologics, Application Outlook (Revenue - USD Billion, 2018 - 2030)

• Spinal Fusion
• Trauma Repair
• Osteoarthritis and Degenerative Arthritis
• Soft Tissue Injuries
• Maxillofacial and Dental Applications
• Reconstructive Surgery

Orthobiologics, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

• Hospitals
• Orthopedic Clinics
• Ambulatory Care Centers
• Research and Academic Institutes
• Others

Orthobiologics, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

• North America
  • U.S
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa